Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chemical modifiers in radiotherapy].

T Nagashima1, K Takakura

  • 1Dept. of Neurosurgery, Univ. of Tokyo.

Gan No Rinsho. Japan Journal of Cancer Clinics
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differentiation of the radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases: importance of multi-voxel proton MRS.

Minimally invasive neurosurgery : MIN·2005
Same author

Simple biodosimetry method for use in cases of high-dose radiation exposure that scores the chromosome number of Giemsa-stained drug-induced prematurely condensed chromosomes (PCC).

International journal of radiation biology·2005
Same author

Chromosomal aberrations in normal human cells induced by the auger effect via Ca atoms.

International journal of radiation biology·2005
Same author

A new concept of three-dimensional endoscope for endoscopic surgery.

Surgical endoscopy·2004
Same author

C-erbB-2 or mutant Ha-ras induced malignant transformation of immortalized human ovarian surface epithelial cells in vitro.

British journal of cancer·2003
Same author

Propofol anesthesia during rhabdomyolysis.

Journal of anesthesia·2003

Bromodeoxyuridine (BrdU) enhances radiation therapy for malignant gliomas. Interferon-beta (IFN-beta) combined with ACNU and radiation shows promising results for improving patient survival and local control.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Pharmacology

Context:

  • Malignant gliomas are aggressive brain tumors with limited treatment options.
  • Radiotherapy is a cornerstone of malignant glioma treatment, but its efficacy can be enhanced by chemical modifiers.
  • Historically, bromodeoxyuridine (BrdU) and misonidazole have been explored as radiosensitizers with varying success.

Purpose:

  • To review the historical and current use of chemical modifiers in enhancing radiotherapy for malignant gliomas.
  • To evaluate the efficacy of different radiosensitizers and biological response modifiers (BRMs) in improving patient outcomes.
  • To highlight the potential of interferon-beta (IFN-beta) as a promising chemical modifier in combination therapy.

Summary:

  • Bromodeoxyuridine (BrdU) has been used as a radiosensitizer for malignant gliomas since the 1960s, with recent intravenous administration proving effective.

Related Experiment Videos

  • Misonidazole, a hypoxic cell sensitizer, showed limited clinical benefit in brain tumor trials.
  • Synchronized chemoradiotherapy using alkaloid and alkyl agents demonstrated improved survival initially, but subsequent studies with alkyl agents like BCNU and ACNU showed no survival prolongation.
  • Interferon-beta (IFN-beta) combined with ACNU and radiation therapy significantly increased response rates (41.2%) compared to ACNU and radiation alone (19.6%), suggesting its potential as a chemical modifier.

    • Impact:

    • The findings underscore the ongoing need for effective chemical modifiers, including BRMs, to improve local control and survival in malignant glioma patients.
    • Interferon-beta (IFN-beta) emerges as a promising agent for combination therapy, warranting further investigation.
    • Continued research into novel irradiation techniques and chemical modifiers is crucial for advancing malignant glioma treatment.